Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.36 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154109 | 1.00 | HTR6 (0.51) | HTR6ALOX5ALKBH3ALDH1A1LMNA | |
| SCHEMBL14718253 | 0.95 | HTR6 (0.55) | HTR6 | |
| SCHEMBL13570638 | 0.92 | HTR6 (0.42) | HTR6 | |
| SCHEMBL2153502 | 0.90 | HTR6 (0.50) | HTR6ALOX5 | |
| SCHEMBL2153513 | 0.90 | HTR6 (0.50) | HTR6ALOX5 | |
| SCHEMBL2154247 | 0.90 | HTR6 (0.54) | HTR6RAB9A | |
| SCHEMBL2153686 | 0.90 | HTR6 (0.52) | HTR6ALDH1A1MAPK1RAB9A | |
| SCHEMBL2153626 | 0.90 | HTR6 (0.48) | HTR6 | |
| SCHEMBL14718517 | 0.87 | HTR6 (0.45) | HTR6ALDH1A1MAPK1RAB9A | |
| SCHEMBL2153166 | 0.87 | HTR6 (0.44) | HTR6ALKBH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519527-B1 | THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2013-12-18 | — | — | EP | claimed |
| US-20130053401-A1 | THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2013-02-28 | — | — | US | claimed |
| EP-2519527-A1 | THIENO [2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | Poxel (FR) | 2012-11-07 | — | — | EP | claimed |
| WO-2011080277-A1 | THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2011-07-07 | — | — | WO | claimed |
| US-9365584-B2 | Thieno [2,3-B] pyridinedione activators of AMPK and therapeutic uses thereof | POXEL (FR) | 2016-06-14 | — | — | US | disclosed |
| EP-2519527-B1 | THIENO[2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2013-12-18 | — | — | EP | disclosed |
| US-20130053401-A1 | THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | POXEL (FR) | 2013-02-28 | — | — | US | disclosed |
| EP-2519527-A1 | THIENO [2,3-B]PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | Poxel (FR) | 2012-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053401-A1 | THIENO [2,3-B] PYRIDINEDIONE ACTIVATORS OF AMPK AND THERAPEUTIC USES THEREOF | PRKAB1, PRKAG1, PRKAB2 | HTR6 2378/4885ALOX5 1070/4885ALKBH3 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.